CRCharles River Laboratories CRL · NYSE
$300.27 -1.95% (-$5.97)
- Market cap
- $14.8B
- Enterprise value
- $17.6B
- P/E
- -
- Forward P/E
- 26.3x
- PEG
- -
- P/S
- 3.7x
- P/FCF
- 39.8x
- EV/EBITDA
- 79.8x
- ROIC
- 10.0%
- Gross margin
- 32.2%
- Net margin
- -6.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 12.9x
- Beta
- 1.40
- Free float
- 98.0%
About the company
Charles River Laboratories International, Inc. (CRL) is an American company operating in the biotechnology and pharmaceutical research industry. The company specializes in providing preclinical and clinical services to pharmaceutical and biotechnology companies, academic institutions, and government organizations. Its services include drug testing, toxicity studies, pharmacokinetics, viral safety testing, genetic analysis, and other biological and chemical analyses. Charles River Laboratories has a broad portfolio of laboratory and clinical services that are crucial for the development of new drugs and treatment protocols. The company emphasizes quality, innovation, and ethical standards in its research and laboratory practices. It is recognized as a significant partner for the pharmaceutical and biotechnology sectors. Charles River Laboratories International, Inc. (CRL) shares are publicly traded on the stock exchange and may represent an attractive investment opportunity for investors monitoring the biotechnology and pharmaceutical industry and seeking investments in a company with a significant position in drug research and development.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Birgit Girshick
Employees
19,000
Headquarters
Wilmington
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number